Leerink Partnrs Analysts Boost Earnings Estimates for Inspire Medical Systems, Inc. (NYSE:INSP)

Inspire Medical Systems, Inc. (NYSE:INSP) – Investment analysts at Leerink Partnrs upped their Q4 2024 earnings per share (EPS) estimates for shares of Inspire Medical Systems in a report released on Thursday, March 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of $0.42 per share for the quarter, up from their prior forecast of $0.41. The consensus estimate for Inspire Medical Systems’ current full-year earnings is ($0.35) per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $0.98 EPS, FY2026 earnings at $2.43 EPS, FY2027 earnings at $4.13 EPS and FY2028 earnings at $5.12 EPS.

Several other research analysts also recently weighed in on the company. Jefferies Financial Group assumed coverage on Inspire Medical Systems in a research note on Friday, January 19th. They set a “buy” rating and a $245.00 target price on the stock. Morgan Stanley assumed coverage on Inspire Medical Systems in a research note on Tuesday, March 19th. They set an “overweight” rating and a $250.00 target price on the stock. KeyCorp assumed coverage on Inspire Medical Systems in a research note on Tuesday, February 6th. They set an “overweight” rating and a $278.00 target price on the stock. Wells Fargo & Company downgraded Inspire Medical Systems from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $245.00 to $187.00 in a research note on Wednesday, December 13th. Finally, Mizuho restated a “buy” rating and set a $250.00 target price on shares of Inspire Medical Systems in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $271.29.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $215.02 on Friday. Inspire Medical Systems has a 1-year low of $123.27 and a 1-year high of $330.00. The stock’s fifty day moving average price is $198.23 and its 200 day moving average price is $181.19.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.53. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The business had revenue of $192.51 million for the quarter, compared to the consensus estimate of $186.75 million. During the same period last year, the business posted $0.10 EPS. The business’s revenue was up 39.6% compared to the same quarter last year.

Insider Activity

In other news, CTO John Rondoni sold 4,387 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $194.40, for a total value of $852,832.80. Following the completion of the transaction, the chief technology officer now owns 11,270 shares of the company’s stock, valued at approximately $2,190,888. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Jerry C. Griffin sold 554 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $198.05, for a total value of $109,719.70. Following the completion of the transaction, the director now owns 9,744 shares of the company’s stock, valued at approximately $1,929,799.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO John Rondoni sold 4,387 shares of the business’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $194.40, for a total value of $852,832.80. Following the completion of the transaction, the chief technology officer now directly owns 11,270 shares of the company’s stock, valued at approximately $2,190,888. The disclosure for this sale can be found here. Insiders sold a total of 21,339 shares of company stock valued at $4,003,381 in the last quarter. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP boosted its position in Inspire Medical Systems by 72.8% during the third quarter. Wellington Management Group LLP now owns 976,972 shares of the company’s stock worth $193,870,000 after purchasing an additional 411,480 shares in the last quarter. Seven Eight Capital LP purchased a new position in Inspire Medical Systems during the third quarter worth approximately $1,558,000. Charles Schwab Investment Management Inc. boosted its position in Inspire Medical Systems by 3.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 256,222 shares of the company’s stock worth $50,845,000 after purchasing an additional 7,838 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Inspire Medical Systems during the third quarter valued at approximately $1,452,000. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Inspire Medical Systems by 29.7% during the third quarter. Canada Pension Plan Investment Board now owns 40,200 shares of the company’s stock valued at $7,977,000 after acquiring an additional 9,200 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.